Breaking News Instant updates and real-time market news.

MOH

Molina Healthcare

$113.07

-2.66 (-2.30%)

, CVS

CVS Health

$65.55

0.06 (0.09%)

07:02
01/03/19
01/03
07:02
01/03/19
07:02

Molina Healthcare renews agreement with CVS Caremark

Molina Healthcare (MOH) announced that, following a comprehensive procurement process, it has extended its agreement with CVS Caremark (CVS) for pharmacy benefit management, or PBM, services through 2021. Under the agreement, which became effective January 1, 2019, CVS Caremark will continue to administer pharmacy benefits for the approximately 4M members Molina serves through its Medicaid, Medicare, and Marketplace health plans. The extension modifies Molina's existing agreement with CVS Caremark to align Molina's pharmacy management strategy with the operational improvement initiatives that have been underway over the last year under its new management team. The agreement is immediately accretive to earnings and will enable Molina to remain responsive to state partner requirements as it manages its nearly $3B of annual pharmacy expenses in an evolving government-sponsored health care landscape. This PBM initiative is one of several that Molina has pursued to lower its costs, including clinical strategies with formulary, utilization management and generic dispensing initiatives, while improving health outcomes for members.

MOH

Molina Healthcare

$113.07

-2.66 (-2.30%)

CVS

CVS Health

$65.55

0.06 (0.09%)

  • 14

    Jan

MOH Molina Healthcare
$113.07

-2.66 (-2.30%)

12/28/18
PIPR
12/28/18
NO CHANGE
PIPR
Piper says buy Centene, sell Community Health if recession were to occur
After performing a recession risk/reward for Hospitals and Managed Care Organizations, Piper Jaffray analyst Sarah James recommends buying Centene (CNC) and selling Community Health Systems (CYH) if a recession were to occur. The analyst says that with some economists calling for a recession in 2019, she dug into the potential impacts across the hospital and insurance sector. For hospitals, consumer surveys point to economic outlook impacting decisions to receive services, James tells investors in a research note. On the other hand, insurers are a "natural defensive sector in a recession," adds the analyst. As such, in a recession James would be adding exposure to insurers and lightening hospitals.
11/13/18
JEFF
11/13/18
UPGRADE
Target $169
JEFF
Buy
Jefferies upgrades Molina to Buy on confidence in earnings stability
Jefferies analyst David Windley upgraded Molina Healthcare to Buy from Hold and raised his price target for the shares to $169 from $152. Despite raising earnings guidance, concern about earnings sustainability has pulled the stock down 14% from recent highs, Windley tells investors in a research note. The analyst says that while Healthcare Exchange margin pressure and reduced revenue in Florida and New Mexico are risks, Molina's cost initiatives plus organic growth "will more than offset headwinds." He views the stock's valuation as attractive at current share levels and has increased coincidence in the company's earnings stability.
11/13/18
JEFF
11/13/18
UPGRADE
Target $169
JEFF
Buy
Molina Healthcare upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Molina Healthcare to Buy and raised his price target for the shares to $169 from $152.
11/07/18
MSCO
11/07/18
NO CHANGE
MSCO
Split Congress 'best outcome' for MCOs and hospitals, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak contends that the Democratic party retaking the majority in the House of Representatives and Republicans retaining the Senate is the "best outcome" for Managed Care Organizations and hospitals, stating that he now sees another attempt at a repeal/replace of the Affordable Care Act as "off the table." The split Congress could also lower the volume on the "Medicare for All" debate given a lack of mandate from either the Democratic or Republican party, Sopcak tells investors. The election results remove a key overhang for Centene (CNC) and Molina (MOH), which he views as most exposed to the ACA marketplace, and to a lesser extent the hospitals, Sopcak added. With ACA repeal/replace off the table, and given the longer term potential upside from Medicaid expansion in Utah and Idaho as expansion ballot initiatives appear to be passing in both states, Sopcak said Molina is emerging as his top pick in the space heading into the final weeks of 2018. Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
CVS CVS Health
$65.55

0.06 (0.09%)

12/18/18
LEHM
12/18/18
INITIATION
Target $91
LEHM
Overweight
Barclays starts CVS Health at Overweight after 'transformational' merger
Barclays analyst Steve Valiquette initiated coverage CVS Health with an Overweight rating and $91 price target. The analyst views the company's acquisition of Aetna as "well-timed" and "transformational." The good news for CVS is that Aetna has substantial leverage to the organic growth of the Medicare Advantage market, Valiquette tells investors in a research note. He projects 15% Medicare Advantage membership for Aetna in both 2019 and 2020. Further, for the combined company, Valiquette believes the $750M-plus in projected synergies by year two "should be more than achievable." The 2019 guidance in February "will be a clearing event for the stock," says the analyst.
12/18/18
LEHM
12/18/18
INITIATION
Target $91
LEHM
Overweight
CVS Health initiated with an Overweight at Barclays
Barclays analyst Steve Valiquette started CVS Health with an Overweight rating and $91 price target. The analyst views the acquisition of Aetna as well-timed and believes it will offset the company's slower growth in retail and pharmacy benefits.
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Goldman downgrades Walgreens to Sell with $68 target, sees downside in 2019
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst says he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also keeps a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).
12/11/18
LEER
12/11/18
NO CHANGE
Target $100
LEER
Outperform
CVS Health assumed with an Outperform at Leerink
Leerink analyst Ana Gupte assumed coverage of CVS Health (CVS) with an Outperform rating and $100 price target. The analyst views the recently raised synergy guidance as having upside with earlier pull-through in 2019 despite the headwind from divestiture of Aetna (AET) Part D lives. Pricing and underwriting remain firm in 2019 based on her MEDACorp fully insured employer broker survey and she is comfortable on stable Commercial margins for the Aetna book. Further, Gupte sees the PBM business as being oversold as it is synergistically integrated with Aetna's MCO book over time into a full-service captive offering. Retail headwinds from e-commerce look largely priced into consensus estimates while multiples have compressed on fears of Amazon's (AMZN) entry into pharmacy, she contends.

TODAY'S FREE FLY STORIES

BXRX

Baudax Bio

$4.66

-0.59 (-11.24%)

07:24
11/22/19
11/22
07:24
11/22/19
07:24
Initiation
Baudax Bio initiated  »

Baudax Bio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.89

1.41 (2.69%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Biohaven Pharmaceutical initiated  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$56.84

0.455 (0.81%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Bristol-Myers initiated  »

Bristol-Myers resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ENR

Energizer

$49.05

1.33 (2.79%)

07:22
11/22/19
11/22
07:22
11/22/19
07:22
Recommendations
Energizer analyst commentary  »

Energizer Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,734.99

-10.51 (-0.60%)

, MSFT

Microsoft

$149.46

-0.14 (-0.09%)

07:20
11/22/19
11/22
07:20
11/22/19
07:20
Periodicals
Amazon suit to likely delay start of Pentagon technology program, Bloomberg says »

Amazon (AMZN) could…

AMZN

Amazon.com

$1,734.99

-10.51 (-0.60%)

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

ABCB

Ameris Bancorp

$42.81

-0.4 (-0.93%)

07:19
11/22/19
11/22
07:19
11/22/19
07:19
Recommendations
Ameris Bancorp analyst commentary  »

Ameris Bancorp subpoena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BWEN

Broadwind Energy

$1.44

-0.06 (-4.00%)

07:18
11/22/19
11/22
07:18
11/22/19
07:18
Hot Stocks
Broadwind Energy receives first solar market order »

Broadwind Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$1.51

-0.06 (-3.83%)

07:18
11/22/19
11/22
07:18
11/22/19
07:18
Hot Stocks
Astrotech says 1st Detect sells TRACER 1000s to shipping & logistics company »

Astrotech Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGS

Medigus

$1.76

(0.00%)

07:17
11/22/19
11/22
07:17
11/22/19
07:17
Hot Stocks
Medigus receives $1.2M payment as part of MUSE agreement in China »

Medigus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:16
11/22/19
11/22
07:16
11/22/19
07:16
Hot Stocks
Breaking Hot Stocks news story on Destination XL »

Destination XL to close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

T

AT&T

$37.59

0.415 (1.12%)

07:15
11/22/19
11/22
07:15
11/22/19
07:15
Recommendations
AT&T analyst commentary  »

AT&T near-term short…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:15
11/22/19
11/22
07:15
11/22/19
07:15
Hot Stocks
Destination XL expects FY19 free cash flow to be breakeven »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

ANIX

Anixa Biosciences

$3.50

-0.11 (-3.05%)

07:13
11/22/19
11/22
07:13
11/22/19
07:13
Hot Stocks
Anixa Biosciences announces Cchek study collaboration with UCA »

Anixa Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:13
11/22/19
11/22
07:13
11/22/19
07:13
Earnings
Destination XL reports Q3 adj. EPS (8c) vs. (2c) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:11
11/22/19
11/22
07:11
11/22/19
07:11
Hot Stocks
Destination XL announces Ujjwal Dhoot as chief digital officer »

Destination XL announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

TREE

LendingTree

$365.30

-5.29 (-1.43%)

07:11
11/22/19
11/22
07:11
11/22/19
07:11
Initiation
LendingTree initiated  »

JPMorgan starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ENR

Energizer

$49.05

1.33 (2.79%)

07:09
11/22/19
11/22
07:09
11/22/19
07:09
Hot Stocks
Energizer targets 'top-line growth above category' in FY20-FY22 »

Also targets adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$2.85

-0.05 (-1.72%)

07:08
11/22/19
11/22
07:08
11/22/19
07:08
Hot Stocks
Neovasc says Reducer featured during therapy development program in Coburg »

Neovasc announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$60.22

0.85 (1.43%)

07:08
11/22/19
11/22
07:08
11/22/19
07:08
Recommendations
ConocoPhillips analyst commentary  »

ConocoPhillips price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJM

J.M. Smucker

$104.40

-1.15 (-1.09%)

07:08
11/22/19
11/22
07:08
11/22/19
07:08
Hot Stocks
J.M. Smucker CEO says Q2 sales performance did not meet expectations »

"While our second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

LHCG

LHC Group

$131.10

0.57 (0.44%)

07:06
11/22/19
11/22
07:06
11/22/19
07:06
Hot Stocks
LHC Group, Texas Health, Methodist Health purchase Healthcare Resources »

LHC Group, Texas Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

SJM

J.M. Smucker

$104.40

-1.15 (-1.09%)

07:06
11/22/19
11/22
07:06
11/22/19
07:06
Earnings
J.M. Smucker cuts FY20 adj. EPS view to $8.10-$8.30 from $8.35-$8.55 »

Consensus $8.27. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

RMR

RMR Group

$48.26

0.02 (0.04%)

07:06
11/22/19
11/22
07:06
11/22/19
07:06
Earnings
RMR Group reports Q4 adj. EPS 59c, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

NAVB

Navidea

$0.71

-0.0322 (-4.34%)

07:05
11/22/19
11/22
07:05
11/22/19
07:05
Initiation
Navidea initiated  »

Navidea initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
11/22/19
11/22
07:05
11/22/19
07:05
General news
FX Update: The dollar has been trading steady-to-firmer »

FX Update: The dollar has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.